Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

January 23, 2017

Primary Completion Date

March 12, 2020

Study Completion Date

March 12, 2020

Conditions
B-Cell Non Hodgkin Lymphoma
Interventions
DRUG

Blinatumomab

Blinatumomab monotherapy

Trial Locations (31)

1200

Research Site, Brussels

2065

Research Site, St Leonards

3000

Research Site, Leuven

3004

Research Site, Melbourne

3052

Research Site, Parkville

4029

Research Site, Herston

6150

Research Site, Murdoch

9000

Research Site, Ghent

14004

Research Site, Córdoba

15706

Research Site, Santiago de Compostela

16132

Research Site, Genova

21201

Research Site, Baltimore

24127

Research Site, Bergamo

28034

Research Site, Madrid

28041

Research Site, Madrid

29607

Research Site, Greenville

30008

Research Site, Murcia

33100

Research Site, Udine

47012

Research Site, Valladolid

50134

Research Site, Florence

56100

Research Site, Pisa

73104

Research Site, Oklahoma City

90146

Research Site, Palermo

91010

Research Site, Duarte

H1T 2M4

Research Site, Montreal

00161

Research Site, Roma

00918

Research Site, San Juan

08025

Research Site, Barcelona

BS2 8ED

Research Site, Bristol

NG5 1PB

Research Site, Nottingham

S10 2JF

Research Site, Sheffield

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY

NCT02910063 - Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL | Biotech Hunter | Biotech Hunter